Physician profile
David W Lin
NPI 1427262906
$21,632.86
in general payments reported to CMS, 2019-2025
23 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $53.47 · 2021: $68.56 · 2022: $11K · 2023: $3,602 · 2024: $5,759 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,663 · Food and Beverage: $1,139 · Travel and Lodging: $43.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,662.50 |
| Food and Beverage | $1,139.18 |
| Travel and Lodging | $43.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19,965.19 | 2022-2024 | Ensite Precision, Ensite |
| W. L. Gore & Associates, INC. | $371.01 | 2023-2025 | Gore Seamguard Bioabsorbable Staple Line Reinforce, Gore Synecor Biomaterial |
| Ethicon US, LLC | $219.57 | 2019-2024 | Echelon Flex, Echelon Endopath, Vistaseal |
| Merck Sharp & Dohme LLC | $203.12 | 2020-2025 | Bridion |
| Takeda Pharmaceuticals U.S.A., INC. | $182.17 | 2020-2024 | Gattex |
| Springworks Therapeutics, INC. | $118.36 | 2025 | Ogsiveo |
| Medical Device Business Services, INC. | $102.50 | 2024 | Enseal |
| Intuitive Surgical, INC. | $65.67 | 2019 | |
| Convatec INC. | $44.02 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $38.98 | 2022 | |
| Tersera Therapeutics LLC | $30.83 | 2025 | Prialt |
| Baudax Bio INC. | $30.76 | 2020-2021 | |
| Innovation Technologies INC | $30.04 | 2025 | Irrisept |
| Ferring Pharmaceuticals INC. | $29.92 | 2021 | |
| Medtronic, INC. | $28.06 | 2023 | Parietene Ds |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.67 | 2025 | |
| Smith+Nephew, INC. | $24.96 | 2019 | |
| Teleflex LLC | $24.43 | 2019 | |
| Amgen INC. | $23.77 | 2022 | |
| Access Pro Medical, LLC | $22.90 | 2025 | Matriderm |
| Sanara Medtech INC. | $17.57 | 2025 | Celleraterx |
| Shire North American Group INC | $16.83 | 2019 | |
| Vioptix INC | $16.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.